Listen to this story



New Herceptin Treatment Found to Treat Breast Cancer

2 min read

Thanks to research by the Institute of Cancer Research in London, together with the Royal Marsden NHS Foundation and funding from Synthon Biopharmaceuticals, it was found that Herceptin can effectively treat a type of breast cancer known as HER2, especially when the Women have failed to respond to other treatments.

New Herceptin Treatment Found to Treat Breast Cancer – Health – WebMediums

HER2 promotes the growth of cancer cells which makes it impossible for a woman to be cured of breast cancer. In addition to proving effective in women with high levels of HER2 in their tumor, the treatment also showed positive results in a group of women with low levels of HER2 protein who had no other treatment options.

The team examined the new treatment for the first time, establishing a link between the chemotherapy agent duocarmazine and trastuzumab, also known as Herceptin, which recognizes the HER2 protein. I affirm the London Cancer Research Institute.

Women with HER2-positive breast cancer who received the treatment lived longer for 7.6 months after starting treatment with no signs of disease progression, which until now has been difficult to achieve.

On the other hand, those women with lower HER2 levels reported no disease progression for up to 4.9 months after starting treatment.

This concludes that the drug managed to extend the life of women who had no other cure. The antibody guides the drug bound to the HER2 protein on the surface of cancer cells.After the two cells, joined by a "linker" that forms the antibody conjugate, enter the cancer cell enzymes into the cell breaking the linker, releasing the cytotoxic drug, which causes damage to the cancer cell's DNA.This process delivers the drug directly to the targeted cancer cells.The method selectively targets cancer cells, minimizing damage to surrounding cells, thus reducing toxicity and side effects for the patient. I explain the Institute of Cancer Research in London in the report delivered